Abstract 1635P
Background
Assessment of germline BRCA1-2 pathogenic variants (gPV) is routinely recommended in Pancreatic Ductal Adenocarcinoma (PDAC) patients (pts), due to clinical-epidemiological relevance. Limited data are available on the prevalence of gPV in other cancer predisposition genes, including the DNA Damage Response (DDR) system.
Methods
Clinical data of consecutive PDAC pts, of any age and stage, tested with a multigene germline panel between January 2018 and March 2023 in five Italian Institutes were collected. A descriptive analysis of gPV (class 4 and 5) frequency, clinical variables and risk factors, was performed. Since gene panels did not overlap across all Institutes, it was difficult to properly estimate the real prevalence of gPV and to compare the clinical characteristics of all wild type with any-PV population, as screened pts/gene also varied (291-1200). Herein we report the best scenario that may result in rates underestimation.
Results
Among the 1200 pts included in the analysis, 169 (14%) had a gPV (any-PV). 23/73 genes had a gPV in ≥ 1 patient. Genes with a gPV in >1% of tested pts were ATM (36/1200 - 3.0%), BRCA2 (35/1200 - 2.9%), CDKN2A (23/942 - 2.4%), BRCA1 (18/1200 - 1.5%), CHEK2 (11/838 - 1.3%), and COL7A1 (5/447 - 1.1%). Characteristics of the main cohorts are shown in the table. The risk of having a genomic gPV was ≥9% in all the subgroups of pts considered for the different variables, including >73 years old pts (11%). Moreover, 25% of pts with age 41-50, 18% of obese pts and 21% of pts with PDAC/breast/ovarian/prostate cancer/melanoma family history harbored a gPV.
Table: 1635P
Patients’ characteristics [N (%)]
Wild Type1031 | Any Pathogenic Variant169 | BRCA1-2 53 | ATM36 | CDKN2A23 | |
Age | |||||
Median | 66 | 63 | 60 | 63 | 64 |
Range | 28-89 | 26-83 | 44-79 | 38-83 | 51-83 |
≤50 | 84 (8) | 24 (14) | 10 (19) | 5 (14) | 0 |
51-73 | 753 (73) | 122 (72) | 41 (77) | 25 (69) | 18 (78) |
≥74 | 194 (19) | 23 (14) | 2 (4) | 6 (17) | 5 (22) |
Gender | |||||
Female | 525 (51) | 79 (47) | 26 (49) | 14 (39) | 10 (43) |
Stage | |||||
I-II | 256 (27) | 32 (21) | 6 (12) | 12 (38) | 5 (26) |
III | 192 (20) | 31 (20) | 10 (19) | 8 (26) | 2 (11) |
IV | 511 (53) | 92 (59) | 36 (69) | 11 (36) | 12 (63) |
NA | 72 | 14 | 1 | 5 | 4 |
CA19.9 | |||||
Median≤35 | 648191 (22) | 73824 (17) | 9838 (18) | 3882 (6) | 1037 (44) |
>35 | 666 (78) | 113 (83) | 36 (82) | 29 (94) | 9 (56) |
NA | 174 | 32 | 9 | 5 | 7 |
Family history | |||||
Yes | 383 (41) | 103 (65) | 38 (75) | 21 (64) | 15 (79) |
No | 554 (59) | 55 (35) | 13 (25) | 12 (36) | 4 (21) |
NA | 94 | 11 | 2 | 3 | 4 |
NA: not available
Conclusions
Our study highlighted a remarkable prevalence of gPV in cancer predisposition and DDR genes in a large cohort of PDAC pts. These findings endorse the implementation of an extended multigene germline panel to be offered to all PDAC pts, irrespective of age, stage, and personal/family history.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
M. Reni.
Funding
Has not received any funding.
Disclosure
G. Giordano: Financial Interests, Personal and Institutional, Advisory Board: AstraZeneca, Bayer; Financial Interests, Personal and Institutional, Financially compensated role: Servier, Amgen, Seagen, Novartis, Ipsen. M. Reni: Financial Interests, Personal and Institutional, Advisory Board: Eli Lilly, Panavance, Celgene, AstraZeneca, Viatris, Merck Sharp & Dohme, Servier, Sotio, Baxter; Financial Interests, Personal and Institutional, Research Grant: AstraZeneca. All other authors have declared no conflicts of interest.
Resources from the same session
1624P - Predictive factors for treatment success of second-line Nal-IRI/5-FU/FA in patients with metastatic pancreatic ductal adenocarcinoma (PDAC) (AIO-PAK-0216)
Presenter: Manfred Lutz
Session: Poster session 22
1626P - A novel endoscopic ultrasound guided extended-release siRNA implant targeting KRASG12D/V in localized pancreatic cancer
Presenter: Anna Varghese
Session: Poster session 22
1629P - Modified-FOLFIRINOX-losartan followed by chemoradiotherapy for locally advanced pancreatic cancer: A phase II study
Presenter: Alshaimaa Alhanafy
Session: Poster session 22
1630P - Phase I/Ib study of SHP2-ERK inhibition in KRASm pancreatic cancer (SHERPA trial) and preclinical identification of potential resistance markers
Presenter: Ashwini Cheryl Kanhailal
Session: Poster session 22
1631P - Phase I study of endoscopic ultrasound (EUS)-guided NBTXR3 delivery activated by radiotherapy (RT) for locally advanced or borderline resectable pancreatic cancer (LAPC or BRPC)
Presenter: Gabriela Fuentes
Session: Poster session 22
1632P - Organoids as tools for functional precision oncology in advanced pancreatic cancer
Presenter: Alice Boileve
Session: Poster session 22
1633P - Development and clinical validation of news transcriptomic tools for predicting the response to individual drug of the mfolfirinox regimen in patients with pancreatic ductal adenocarcinoma
Presenter: Nicolas Fraunhoffer
Session: Poster session 22